Reports Q1 revenue $10.3M, consensus $13.69M. “This was an important quarter for Kymera as we are poised to expand our clinical pipeline with an increased focus on immunology. With our STAT6 and TYK2 oral degrader programs, we believe we can significantly impact the way complex immuno-inflammatory diseases are managed with medicines that have the potential to offer biologics-like efficacy with the convenience of oral, daily pills,” said Nello Mainolfi, PhD, Founder, President, and CEO. “Building on our prior scientific achievements in both immunology and oncology, we have established a strong foundation and an industry-leading pipeline positioning Kymera to deliver first-in-class therapies to patients around the world.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
- Cisco downgraded, Lucid resumed: Wall Street’s top analyst calls
- Kymera Therapeutics initiated with an Outperform at Oppenheimer
- Kymera Therapeutics announces presentation at AACR annual meeting
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting